Vaxart (VXRT) investor relations material

Use of proceeds and capital allocation

• Up to $25 million of common stock may be sold to the investor, with proceeds to be used as described in the registration statement or SEC documents.

• The company is restricted from entering into similar equity line arrangements for at least 24 months after the agreement date, except for certain exempt issuances.

Risk factors and disclosures

• The investor acknowledges high risk and the possibility of total loss, and confirms it is an accredited investor.

• The company provides broad indemnification to the investor for misrepresentations, breaches, or claims arising from the transaction, except for fraud or willful misconduct by the investor.

• The agreement includes a 4.99% beneficial ownership limitation for the investor.

• The company affirms compliance with anti-corruption, anti-money laundering, and cybersecurity laws, and maintains appropriate internal controls.

Market opportunity and competitive landscape

• The company’s common stock is listed on the OTCQX Best Market and is eligible for electronic transfer via DTC.

• The company is a smaller reporting company and not a shell company.